Neurophet and AriBio will collaborate to develop an AI-driven platform for diagnosing Alzheimer's disease.
Under the agreement, Neurophet will participate in AriBio's global phase III clinical trial of AR1001, an oral treatment for Alzheimer's disease. Neurophet’s Aqua brain MRI analysis software segments and analyzes brain images and will be used to identify eligible patients for the trial, as well as assess the treatment effect of AR1001. The planned platform will integrate this data with fluid biomarker data from the trial.
Ultimately, the plan is to create a platform that can predict the risk of amyloid-beta protein positivity early by conducting MRI analysis and blood-based biomarker tests, Neurophet said.
